European Medicines Agency updates guideline on evaluation of anticancer medicines
The European Medicines Agency has finalised the revision of its guideline on the evaluation of anticancer medicinal products . This revision includes, amongst other topics:
- the use of biomarkers as an integrated part of the development of medicines;
- combination-therapy studies;
- the choice of endpoints in confirmatory trials.
The Agency is responsible for the evaluation of all new anticancer medicines in the European Union. The guideline provides guidance on all stages of clinical drug development for the treatment of cancer.
Alongside conventional aims such as defining the proper doses and schedule for a medicine, the guideline highlights the importance of identifying the target population during the development. The revised guideline explains how the use of biomarkers throughout non-clinical and clinical development can help identify patients with an increased likelihood to respond favourably to treatment.
Confirmatory trials should demonstrate that the investigational product provides clinical benefit. From both a clinical and a methodological perspective, the most persuasive outcome of a clinical trial is the demonstration of favourable effects on overall survival. Prolonged progression-free survival and disease-free survival are also considered to be of benefit to the patient. The guideline describes how to select the appropriate endpoints for confirmatory studies.
Two appendices complement the guideline, to address methodological considerations for using progression-free survival in confirmatory trials, and to provide condition specific guidance for non-small-cell lung cancer (NSCLC), prostate cancer, chronic myeloid leukaemia (CML), myelodysplastic syndromes and haematopoietic stem cell transplantation.
The revised guideline comes into effect on 1 July 2013.